Viscosupplementation Market by Product (Single Injection, Three Injection, and Five Injection), Application (Knee Osteoarthritis, Hip Osteoarthritis, and Hand Osteoarthritis) End Use (Hospitals, Orthopedic Clinics, and Ambulatory Surgical Centers): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026882 | Pages: 100 | Industry: Medical Device | Date: Oct 2022 | Type: Global

The market crossed US$ 5.26 billion mark in 2022 and is expected to hit US$ 11.01 billion by 2030, recording a CAGR of 9.7% during the forecast period.  

Increasing ageing population drives the growth of viscosupplementation market . Globally, there is an increasing geriatric population who are prone to knee and hip osteoarthritis which decreases the flexibility and strength of the cartilage. According to United Nation, in 2019, about 703 million population are 65 years and above globally. It is expected to double 1.5 billion ageing population in 2050. According to the Government of Canada’s Statistics report, in 2019, the Canadian ageing population was 6,592,11 which accounts for 17.5% of the total population. The single injection viscosupplementation segment is expected to dominate the market due to rising product launch and reduction of injection volume which is easier for application and comfortable for patients.

Within the report, the market is segmented into product, application, end use, and geography. By product, the market is further segmented into single injection, three injection, and five injection. Based on application, the market is segmented into osteoarthritis, hip osteoarthritis, and hand osteoarthritis. By end use, the market is categorized into hospitals, orthopedic clinics, and ambulatory surgical centers. Geographically, the market is subsegmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Get more information on this report :

Rising awareness about new drugs for treatment.

Knee osteoarthritis is the major cause of disability among geriatric population.  According to Centre for Disease Control and Prevention, 2020, knee osteoarthritis affects about 35.5 million US adults. Thus, there is a rising awareness about new drugs for knee-related problems which promotes the growth of viscosupplementation market.

Growing ageing population is expected to drive the viscosupplementation market in Asia pacific and Europe region.

The presence of large ageing population who are more susceptible to osteoarthritis and other disorders in the region driving the growth of viscosupplementation. According to a recent report on SCOPE 2021: a new scorecard for osteoporosis in Europe, 25.5 million women and 6.5 million men in the European Union were affected with osteoporosis in 2019.

Further, there is an increasing initiative by key players which results in increased investments in R&D which propels the growth of viscosupplementation.

Recent strategic developments in viscosupplementation market

The viscosupplementation market has undergone several significant developments, and a few of these have been mentioned below:

  • In August 2021, Seikagaku Corporation launched HyLink which is an intra-articular single injection viscosupplement for the treatment of knee osteoarthritis in Taiwan.
  • In January 2021, Nuvo Pharmaceuticals Inc. launched NeoVisc+ 2 mL and NeoVisc ONE 4 mL in Canada. This is used in the treatment joint functionality and pain in patients suffering from degenerative or mechanical arthropathy of the knees.

The viscosupplementation market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Sanofi; Anika Therapeutics, Inc; Seikagaku Corp; Zimmer Biomet; Smith & Nephew PLC; Ferring Pharmaceuticals BV; Lifecore Biomedical; LG Life Science Ltd; Fidia Farmaceutici SpA; and F. Hoffmann-La Roche Ltd. are among the prominent players operating in the market.

Target audience for the report:

  • Hospitals
  • Ambulatory Surgical Centers
  • Orthopedic Centers

Scope of the report:

In this report, the market has been segmented based on:

  • Product
    • Single Injection
    • Three Injection
    • Five Injection
  • Application
    • Knee Osteoarthritis
    • Hip Osteoarthritis
    • Hand Osteoarthritis
  • End Use
    • Hospitals
    • Orthopedic Clinics
    • Ambulatory Surgical Centers
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
    • Sanofi
    • Anika Therapeutics, Inc
    • Seikagaku Corp
    • Zimmer Biomet
    • Smith & Nephew PLC
    • Ferring Pharmaceuticals BV
    • Lifecore Biomedical
    • LG Life Science Ltd
    • Fidia Farmaceutici SpA
    • F. Hoffmann-La Roche Ltd.

The List of Companies
- Sanofi
- Anika Therapeutics, Inc
- Seikagaku Corp
- Zimmer Biomet
- Smith & Nephew PLC
- Ferring Pharmaceuticals BV
- Lifecore Biomedical
- LG Life Science Ltd
- Fidia Farmaceutici SpA
- F. Hoffmann-La Roche Ltd.

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$2000
Site License
$3000
Enterprise License
$4000